logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Genesis Drug Discovery & Development (Gd3), A Member Of Genesis Global Group, Acquires Jss Medical Research To Expand Its Clinical Services Portfolio

May 10, 2023•over 2 years ago

Acquiring Company

Genesis Drug Discovery & Development

Acquired Company

JSS Medical Research

PharmaceuticalBiotechnologyHealth CareBiotechnologyHealth CareMedical

Description

Genesis Drug Discovery and Development (GD3), Contract Research Organization (CRO) arm and member of Genesis Global Group (GGG), announced today that it has acquired JSS Medical Research. With corporate headquarters in Montreal, Canada, and regional offices in Bogotá, Columbia, Faridabad, India, and Warsaw, Poland, JSS Medical Research provides pre- and post-approval clinical development services to support pharmaceutical, biotechnology, nutraceutical and medical device companies worldwide.

Company Information

Company

Genesis Drug Discovery & Development

About

Genesis Drug Discovery & Development (GD3) is a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-IIII clinical trials. The GD3 worldwide portfolio includes services for HTS and assay development, synthetic organic and medicinal chemistry, DMPK/in-vivo pharmacology and safety pharmacology, toxicology, and clinical trial services for the regulatory approval of novel drug and medical device products. To find out more, please visit www.genesisbiotechgroup.com. Contact: Anthony Rohr, Chief Operating Officer 358744@email4pr.com844-272-8234 SOURCE Genesis Drug Discovery & Development (GD3)

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed